Ind Swift Laboratories
113.37
+4.72(+4.34%)
Market Cap₹925.23 Cr
PE Ratio3.56
IndustryHealthcare
Company Performance:
1D+4.34%
1M+23.83%
6M+6.28%
1Y+9.72%
5Y+60.24%
View Company Insightsright
More news about Ind Swift Laboratories
05Dec 25
Ind-Swift Laboratories Secures Trading Approval for 81.24 Lakh Equity Shares Post-Amalgamation
Ind Swift Laboratories Limited (ISLL) has received trading approval from BSE and NSE for 81,24,698 equity shares with a face value of ₹10 each. These shares, with distinctive numbers from 73486861 to 81611558, were issued as part of the amalgamation scheme with Ind-Swift Limited under Sections 230-232 of the Companies Act, 2013. This approval allows eligible shareholders of the erstwhile Ind-Swift Limited to trade their newly acquired shares on both exchanges, potentially impacting the company's market capitalization and liquidity.
 no imag found
14Nov 25
Ind-Swift Laboratories Reports Fund Utilization Deviations in Monitoring Agency Report
Ind Swift Laboratories Limited (ISLL) has reported a 14.37% deviation in the utilization of funds from its Rs. 314.60 crore preferential issue. Key issues include an unauthorized reimbursement of Rs. 45.21 crore for business expansion and a Rs. 64.09 crore investment in a third-party NBFC. The company cited a recent merger and pursuit of better returns as reasons for these actions. Care Ratings, the monitoring agency, expressed concerns about fund commingling and limited ability to directly ascertain the utilization of issue proceeds.
 no imag found
05Nov 25
Ind-Swift Laboratories Secures NSE Listing Approval, Awaits BSE Clearance for Share Allotment
Ind Swift Laboratories Limited (ISLL) has received listing approval from NSE for equity shares allotted under a scheme of amalgamation with Ind-Swift Limited. The company is awaiting final approval from BSE, which is reportedly under review. ISLL filed listing applications with both exchanges on September 12, 2025. Once BSE approval is received, ISLL will credit shares to shareholders' Demat accounts and apply for trading approval. Shareholders can only trade new shares after both exchanges grant trading approval.
 no imag found
12Sept 25
IND-SWIFT LABORATORIES Ventures into Cricket with 50:50 Joint Venture for Chandigarh Premier League
Ind Swift Laboratories approves a 50:50 joint venture to participate in the inaugural Chandigarh Premier League (CPL). The company will invest up to Rs. 2.00 crores in this Limited Liability Partnership with Mr. Nikhil Goel. The venture aims to sponsor/own a cricket team in the CPL and engage in other sports-related initiatives. This strategic move is driven by cricket's commercial potential in India and the opportunity to establish an early presence in the CPL.
 no imag found
28Aug 25
Ind-Swift Laboratories Promoters Acquire 39.46 Lakh Shares Through Amalgamation Scheme
Ind Swift Laboratories' promoter group acquired 39,46,094 equity shares through an amalgamation scheme approved by the National Company Law Tribunal. Essix Biosciences Limited led the acquisition with 25,55,014 shares. The company's equity share capital increased from INR 73.49 crore to INR 81.61 crore, with total shares rising to 8,16,11,558. This move significantly increased the promoters' stake in the company, with Essix Biosciences now holding 34.04% of total share capital.
 no imag found
13Aug 25
Ind-Swift Lab Reports Q1 EBITDA Turnaround, Revenue Growth Amid Profit Decline
Ind Swift Laboratories Limited reported mixed Q1 financial results. The company achieved an EBITDA turnaround, posting ₹36.00 million compared to a ₹65.00 million loss in the previous year, with an EBITDA margin of 2.36%. Revenue grew by 4.08% to ₹1.53 billion. However, consolidated net profit declined by 69.86% to ₹88.00 million from ₹292.00 million in the same quarter last year. The board approved these unaudited results in a meeting on August 13.
 no imag found
11Aug 25
Ind Swift Laboratories Reports Strong Profit Growth and Completes Merger with Ind Swift Limited
Ind Swift Laboratories Limited (ISLL) announced robust financial results following its merger with Ind Swift Limited. The company reported a standalone net profit of Rs. 256.09 crores and revenue from operations of Rs. 549.65 crores. The merger, approved by NCLT, became effective on August 8. ISLL allotted 14.20 lakh preference shares to former Ind Swift Limited shareholders and converted 15.32 lakh equity warrants. Strategic asset sales and exceptional items contributed Rs. 223.20 crores to profits. The company's standalone EPS stood at Rs. 38.08.
 no imag found
31Jul 25
Ind-Swift Laboratories Merger with Ind-Swift Limited Gets NCLT Approval, Effective August 8, 2025
The National Company Law Tribunal (NCLT) has approved the merger of Ind-Swift Limited with Ind-Swift Laboratories Limited (ISLL). The amalgamation will be effective from August 8, 2025, with March 31, 2024, as the appointed date. The record date for determining eligible shareholders is set for August 14, 2025. Post-merger, ISLL's authorized share capital will increase to Rs. 140.00 crores, comprising 11.50 crore equity shares and 25.00 lakh preference shares. Ind-Swift Limited will be dissolved without winding up. The merger is expected to create operational synergies and potentially strengthen the market position of the combined entity.
 no imag found
28Jul 25
Ind-Swift Laboratories Secures NCLT Approval for Merger with Ind-Swift Limited
Ind Swift Laboratories Limited (ISLL) has obtained final approval from the National Company Law Tribunal (NCLT) for its merger with Ind-Swift Limited. The NCLT Chandigarh Bench approved the amalgamation scheme, which will affect shareholders and creditors of both companies. ISLL has made the NCLT order publicly available on its website for transparency. The merger is expected to streamline operations and create potential synergies between the two entities.
 no imag found
18Jun 25
Ind-Swift Laboratories Invests ₹950 Million in Khandelwal Finance's OCRPS
Ind-Swift Laboratories has approved an investment of ₹950.00 million in Khandelwal Finance through Optionally Convertible Redeemable Preference Shares (OCRPS). This strategic move represents a significant financial decision for the pharmaceutical company, potentially diversifying its investment portfolio and providing opportunities for future equity conversion or steady income through fixed dividends.
 no imag found
28Mar 25
Ind-Swift Laboratories Approves Rs 20 Crore Short-Term Advance to Ashok Investors Trust
Ind-Swift Laboratories Ltd (ISLL) has approved a short-term advance of up to Rs 20 crore to Ashok Investors Trust Limited (AITL), a registered NBFC. The advance is in the form of an Inter-Corporate Deposit with a 30-day term, extendable for another 30 days, at 10% annual interest. The transaction is secured by post-dated cheques and is not a related party transaction. ISLL already holds 800 NCDs of AITL, each with a face value of Rs 5,00,000.
 no imag found
Ind Swift Laboratories
113.37
+4.72
(+4.34%)
1 Year Returns:+9.72%
Industry Peers
Sun Pharmaceutical
1,702.10
(+4.56%)
Divis Laboratories
6,209.00
(+4.31%)
Torrent Pharmaceuticals
4,045.60
(+1.46%)
Cipla
1,322.80
(+0.85%)
Dr Reddys Laboratories
1,235.40
(+4.47%)
Lupin
2,185.90
(+2.65%)
Zydus Life Science
902.90
(+2.64%)
Mankind Pharma
2,162.60
(+4.79%)
Aurobindo Pharma
1,226.10
(+4.71%)
Alkem Laboratories
5,702.50
(+3.28%)